| Rank |
Status |
Study |
| 1 |
Not yet recruiting
|
Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis
| Condition: |
Hyperhidrosis |
| Interventions: |
Drug: Botox (onabotulinumtoxinA); Drug: NeuroBloc/Myobloc (rimabotulinumtoxinB); Drug: NaCl (placebo) |
| Outcome Measures: |
DLQI (Dermatology Life Quality Index); AE (Adverse Events); Gravimetry; HDSS (Hyperhidrosis Disease Severity Scale); Health outcome (EQ-5D); LSAS-SR (Liebowitz Social Anxiety Scale-Self Report); MADRS-S (Montgomery-Asberg Depression Rating Scale-Self report); Global Assessment of Therapy |
|
| 2 |
Not yet recruiting
|
Evaluate the Efficacy of Oxybutynin Chloride in Patients With Primary Hyperhidrosis
| Condition: |
Primary Hyperidrosis |
| Interventions: |
Drug: Oxybutynin; Drug: Placebo |
| Outcome Measures: |
Oxybutynin Chloride efficacy; Perception of improvement; Evaluate therapeutic safety; Quality of life; Time of subject response; Duration of response; Evaluation between quality of life and groups |
|
| 3 |
Recruiting
|
Histological Analysis Following Ulthera System Treatment for Hyperhidrosis
| Condition: |
Hyperhidrosis |
| Intervention: |
Device: Ulthera System Treatment |
| Outcome Measures: |
Reduction in the number of sweat glands from baseline to 90-days post-treatment.; Reduction in spontaneous axillary sweat production assessed by gravimetric method at 90-days post treatment; HDSS score reduction; Starch iodine test |
|
| 4 |
Recruiting
|
Tx Axillary Hyperhidrosis 1210nm Diode Laser
| Condition: |
Axillary Hyperhidrosis |
| Intervention: |
Device: 1210nm Diode Laser treatments |
| Outcome Measures: |
subjective global assessment questionnaire; gravimetric analysis; modified starch-iodine test |
|
| 5 |
Recruiting
|
Comparator Study of the Effect of DRM04B and DRM 04 in Subjects With Axillary Hyperhidrosis
| Condition: |
Hyperhidrosis |
| Interventions: |
Drug: Dose 1 of DRM04B; Drug: Dose 2 of DRM04B; Drug: Dose 1 of DRM04; Drug: Dose 2 of DRM04; Other: Vehicle |
| Outcome Measures: |
Proportion of subjects who have a minimum 1-grade improvement in HDSS from Baseline at Week 4; Proportion of subjects who have a minimum 2-grade improvement in HDSS from Baseline at Week 4; Absolute change in the gravimetrically measured sweat production from Baseline to Week 4; Absolute change in the gravimetrically measured sweat production from Baseline to Week 6; Proportion of subjects who have a minimum 1-grade improvement in HDSS from Baseline at Week 6 |
|
| 6 |
Recruiting
|
A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
| Condition: |
Hyperhidrosis |
| Intervention: |
Drug: BBI-4000 |
| Outcome Measures: |
Percent change in the gravimetrically measured sweat production from baseline; Absolute change in the gravimetrically measured sweat production from baseline; Proportion of subjects who have a minimum of 2-grade improvement in HDSS from baseline.; Proportion of subjects who have a minimum of 1-grade improvement in HDSS from baseline |
|
| 7 |
Recruiting
|
Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects
| Condition: |
Hyperhidrosis |
| Intervention: |
Drug: [14C]Umeclidinium 18.5 mg |
| Outcome Measures: |
PK Assessment (Cmax) for [14C] umeclidinium and total radioactivity; PK Assessment (tmax) for [14C] umeclidinium and total radioactivity; PK Assessment (AUC) for [14C] umeclidinium and total radioactivity; PK Assessment (t1/2) for [14C] umeclidinium and total radioactivity; Compartmental modeling of absorption rate for [14C] umeclidinium; Compartmental modeling of elimination rate for [14C] umeclidinium; Determine the amount of Umeclidinium absorbed in the skin; Safety Assessment for AEs; Safety Assessment for ECGs, and telemetry; Safety Assessment for hematology laboratory parameters; Safety Assessment for measurement of blood pressure; Number of subjects with application site skin irritation; Safety Assessment for clinical chemistry laboratory parameters; Safety Assessment for measurement of pulse rate |
|
| 8 |
Recruiting
|
Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Glycopyrrolate (AIDES-G)
| Conditions: |
Hyperhydrosis; Depression |
| Intervention: |
Drug: Glycopyrrolate |
| Outcome Measures: |
Clinical Global Impression- Improvement scores; change in mean of patient rated severity of sweating for each week, and change in mean skin conductance for each week |
|
| 9 |
Recruiting
|
Efficacy and Safety of Sage Tablets Compared to Placebo in Menopausal Patients With Hot Flushes and Sweating
| Condition: |
Menopausal Hot Flushes |
| Intervention: |
Drug: Sage extract, 3400 mg , DER 1:17 |
| Outcome Measures: |
Change from Baseline Hyperhidrosis Disease Severity Scale; Change from Baseline Menopause Rating Scale / MRS; Change from Baseline Modified Dem Tect |
|
| 10 |
Recruiting
|
Comparison of Methods of Lumbar Sympathetic Ganglion Block: Distance vs Angle
| Condition: |
Lumbar Sympathetic Ganglion Block Indication: Neuropathic Pain, CRPS, Hyperhydrosis Etc. |
| Intervention: |
Procedure: lumbar sympathetic ganglion block |
| Outcome Measures: |
temperature change; muscle or vessel shadow |
|
| 11 |
Not yet recruiting
|
ASIS for Enbrel in Plaque Psoriasis
| Condition: |
Plaque Psoriasis. |
| Interventions: |
Drug: Gadolinium; Drug: Efficacy of Enbrel subcutaneously at Week 12; Drug: Efficacy of Enbrel subcutaneously at Week 24; Drug: Efficacy of Enbrel subcutaneously at Week 36; Drug: Efficacy of Enbrel subdermally at Week 12; Drug: Efficacy of Enbrel subdermally at Week 24; Drug: Efficacy of Enbrel subdermally at Week 36; Drug: PASI 75 n(%) subcutaneously at Week 12; Drug: PASI 75 n(%) subcutaneously at Week 24; Drug: PASI 75 n(%) subcutaneously at Week 36; Drug: PASI 75 n(%) subdermally at Week 12; Drug: PASI 75 n(%) subdermally at Week 24; Drug: PASI 75 n(%) subdermally at Week 36; Drug: Adverse Reactions of Enbrel subcutaneously; Drug: Adverse Reactions of Enbrel subdermally at Week 36 |
| Outcome Measures: |
Relative Prolongation Ability Score for Gadolinium subdermally injected.; Efficacy of Enbrel subcutaneously vs. subdermally in Plaque Psoriasis. |
|
| 12 |
Unknown †
|
Inherited Myokymia: A Clinical and Genetic Study of a Family
| Condition: |
A Study of Clinical and Genetic Mutations in a Family of Neuromyotonia, so Called Isaac's Syndrome |
| Intervention: |
|
| Outcome Measure: |
|
|
| 13 |
Not yet recruiting
|
Single-port Thoracoscopic Sympathicotomy in Complex Regional Pain Syndrome Type I (CRPS)
| Condition: |
Complex Regional Pain Syndrome Type I of the Upper Limb |
| Intervention: |
Procedure: unilateral single-port VATS sympathicotomy |
| Outcome Measures: |
Change in perceived pain measured in Visual Analogue Scale; Change in function in extremity |
|
